Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluating the American Heart Association/American College of Cardiology Guideline-Recommended and Contemporary Pretest Probability Models in a Mixed Asian Cohort: The Contribution of Coronary Artery Calcium.
Baskaran L, Yan L, Tan CS, Ho WW, Tan SY, Williams MC, Han D, Nakanishi R, Cerci RJ, Ng MY, Shaw LJ, Chua TSJ, Douglas P, Winther S. Baskaran L, et al. Among authors: chua tsj. J Am Heart Assoc. 2024 Jul 2;13(13):e033879. doi: 10.1161/JAHA.123.033879. Epub 2024 Jun 27. J Am Heart Assoc. 2024. PMID: 38934865 Free PMC article.
Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease.
Spertus JA, Jones PG, Maron DJ, O'Brien SM, Reynolds HR, Rosenberg Y, Stone GW, Harrell FE Jr, Boden WE, Weintraub WS, Baloch K, Mavromatis K, Diaz A, Gosselin G, Newman JD, Mavromichalis S, Alexander KP, Cohen DJ, Bangalore S, Hochman JS, Mark DB; ISCHEMIA Research Group. Spertus JA, et al. N Engl J Med. 2020 Apr 9;382(15):1408-1419. doi: 10.1056/NEJMoa1916370. Epub 2020 Mar 30. N Engl J Med. 2020. PMID: 32227753 Free PMC article. Clinical Trial.
Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients With Chronic Coronary Disease: Insights From the ISCHEMIA Trial.
Reynolds HR, Cyr DD, Merz CNB, Shaw LJ, Chaitman BR, Boden WE, Alexander KP, Rosenberg YD, Bangalore S, Stone GW, Held C, Spertus J, Goetschalckx K, Bockeria O, Newman JD, Berger JS, Elghamaz A, Lopes RD, Min JK, Berman DS, Picard MH, Kwong RY, Harrington RA, Thomas B, O'Brien SM, Maron DJ, Hochman JS; ISCHEMIA Research Group *. Reynolds HR, et al. J Am Heart Assoc. 2024 Mar 5;13(5):e029850. doi: 10.1161/JAHA.122.029850. Epub 2024 Feb 27. J Am Heart Assoc. 2024. PMID: 38410945 Free PMC article. Clinical Trial.
Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial.
Pracoń R, Spertus JA, Broderick S, Bangalore S, Rockhold FW, Ruzyllo W, Demchenko E, Nageh T, Grossman GB, Mavromatis K, Manjunath CN, Smanio PEP, Stone GW, Mancini GBJ, Boden WE, Newman JD, Reynolds HR, Hochman JS, Maron DJ; ISCHEMIA Research Group. Pracoń R, et al. Circ Cardiovasc Interv. 2024 Jun;17(6):e013435. doi: 10.1161/CIRCINTERVENTIONS.123.013435. Epub 2024 Apr 17. Circ Cardiovasc Interv. 2024. PMID: 38629312 Clinical Trial.
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM; TRILOGY ACS Steering Committee. Chin CT, et al. Am Heart J. 2010 Jul;160(1):16-22.e1. doi: 10.1016/j.ahj.2010.04.022. Am Heart J. 2010. PMID: 20598967 Clinical Trial.
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators. Roe MT, et al. N Engl J Med. 2012 Oct 4;367(14):1297-309. doi: 10.1056/NEJMoa1205512. Epub 2012 Aug 25. N Engl J Med. 2012. PMID: 22920930 Free article. Clinical Trial.
Incidence and Outcomes of Cardiocerebral Infarction: A Cohort Study of 2 National Population-Based Registries.
Ho JS, Zheng H, Tan BY, Ho AF, Foo D, Foo LL, Lim PZ, Liew BW, Ahmad A, Chan BPL, Chang HM, Kong KH, Young SH, Tang KF, Chua T, Hausenloy DJ, Yeo TC, Tan HC, Yip JWL, Chai P, Venketasubramanian N, Chan MY, Yeo LL, Sia CH. Ho JS, et al. Stroke. 2024 Sep;55(9):2221-2230. doi: 10.1161/STROKEAHA.123.044530. Epub 2024 Jul 31. Stroke. 2024. PMID: 39082144
Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study.
Bittner VA, Schwartz GG, Bhatt DL, Chua T, De Silva HA, Diaz R, Goodman SG, Harrington RA, Jukema JW, McGinniss J, Pordy R, Garon G, Scemama M, White HD, Steg PG, Szarek M; ODYSSEY OUTCOMES Investigators. Bittner VA, et al. J Clin Lipidol. 2024 Jul-Aug;18(4):e548-e561. doi: 10.1016/j.jacl.2024.04.122. Epub 2024 Apr 10. J Clin Lipidol. 2024. PMID: 38960812 Free article. Clinical Trial.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Ray KK, et al. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Lancet Diabetes Endocrinol. 2019. PMID: 31272931 Free article. Clinical Trial.
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG; ODYSSEY OUTCOMES Investigators. Goodman SG, et al. Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):342-352. doi: 10.1093/ehjcvp/pvae025. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38658193 Free PMC article. Review.
68 results